Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8531894 | 0.86 | SIRT1 (0.46) | MEN1KMT2ASIRT1POLBALDH1A1 | |
| SCHEMBL2707458 | 0.84 | SIRT1 (0.51) | MEN1KMT2ASIRT1POLBCA12 | |
| SCHEMBL8533938 | 0.83 | ALDH1A1 (0.53) | MEN1KMT2ASIRT1POLBALDH1A1 | |
| SCHEMBL231042 | 0.82 | SIRT1 (0.71) | MEN1KMT2ASIRT1POLBCA12 | |
| SCHEMBL1447741 | 0.82 | KDM4E (0.59) | SIRT1POLBCA12CA1CA2 | |
| SCHEMBL6934354 | 0.82 | SIRT1 (0.53) | SIRT1POLBCA12CA1CA2 | |
| SCHEMBL11760014 | 0.82 | IDO1 (0.51) | MEN1KMT2ACA1CA2KDM4E | |
| SCHEMBL1775501 | 0.81 | POLB (0.56) | MEN1KMT2ASIRT1POLBCA12 | |
| SCHEMBL30401525 | 0.81 | MEN1 (0.51) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL29269657 | 0.81 | MEN1 (0.51) | MEN1KMT2AKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035268-A2 | TAU PATHWAY MODULATORS | QATAR FOUNDATION FOR EDUCATION, SCIENCE AND COMMUNITY DEVELOPMENT (QA) | 2024-02-15 | — | — | WO | disclosed |
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-11-30 | — | — | US | disclosed |
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-11-30 | — | — | US | disclosed |
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-11-30 | — | — | US | disclosed |
| EP-0859757-A1 | DERIVATES OF N,N-DIMETHYL-2-(ARYLTHIO)BENZYLAMINE, THEIR SALTS, METHODS OF PREPARATION AND THEIR USE IN PHARMACEUTICAL MEDICAMENTS | Farmak A.S. (CZ) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997017325-A1 | DERIVATES OF N,N-DIMETHYL-2-(ARYLTHIO)BENZYLAMINE, THEIR SALTS, METHODS OF PREPARATION AND THEIR USE IN PHARMACEUTICAL MEDICAMENTS | FARMAK A.S. (CZ) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381133-A1 | TAU AND AMYLOID PROTEIN LOWERING COMPOUNDS AND METHODS OF USE | MAPT, TTR, HTT | MEN1 2502/4885KMT2A 3052/4885SIRT1 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.